Ventricular Assist Devices (VAD) Market to Register a CAGR of 8.12% by 2032, Driven by Rising Heart Failure Cases and Advancements in Mechanical Circulatory Support | DelveInsight

The ventricular assist devices (VAD) market is set for substantial growth, fueled by the increasing prevalence of advanced heart failure, the growing adoption of mechanical circulatory support systems, and technological advancements enhancing device durability and patient outcomes. Continuous-flow VADs, in particular, are becoming the standard of care, offering improved survival rates and quality of life for patients awaiting heart transplants or receiving destination therapy. Furthermore, expanding indications, rising awareness among healthcare professionals, and favorable reimbursement scenarios are expected to support market expansion through 2032.

DelveInsight's Ventricular Assist Devices (VAD) - Market Insight, Competitive Landscape, and Market Forecast - 2032 report delivers in-depth current and forecast market analysis, leading company market shares, key market drivers, barriers, trends, and profiles of prominent players shaping the competitive landscape.

Explore the latest trends and growth drivers in the ventricular assist devices Market-download your sample report now https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Ventricular Assist Devices Market Report
• The global ventricular assist devices market is projected to experience significant growth, expanding at a CAGR of 8.12%, and reaching a substantial value by 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global ventricular assist devices market during the forecast period.
• Notable ventricular assist devices companies such as Abiomed, Inc., Asahi Kasei Corporation (Evaheart Medical U.S.A., Inc.), Abbott Laboratories (St. Jude Medical, Inc.), Berlin Heart GmbH, Jarvik Heart, Inc., Medtronic Plc., Terumo Corporation, Evaheart, Inc., Calon Cardio, SynCardia Systems LLC, Cardiobridge Gmbhand, LivaNova, Inc., Cirtec, CorWave SA, FineHeart, ReliantHeart Inc., and several others are currently operating in the ventricular assist devices market.
• In April 2025, Medtronic received FDA approval for the OmniaSecureTM defibrillation lead, designed for precise delivery and placement in the right ventricle. The lead, based on the SelectSecureTM Model 3830 pacing lead, treats life-threatening ventricular tachyarrhythmias, ventricular fibrillation, and bradyarrhythmias. At 4.7 French, it is the world's smallest defibrillation lead, suitable for both adults and pediatric patients aged 12 and up, including those with smaller anatomies.
• In April 2025, Orchestra BioMed Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (BDD) for its atrioventricular interval modulation (AVIM) therapy. This designation recognizes the potential of AVIM therapy to address uncontrolled hypertension and cardiovascular risk in a U.S. population of over 7.7 million patients. The therapy is currently being studied in the BACKBEAT global pivotal study, a strategic collaboration with Medtronic.
• In March 2025, Anuncia Medical, Inc. received Breakthrough Device Designation from the FDA for its ReFlow® EVD, an innovative solution for external ventricular drains (EVDs) used to manage brain swelling and elevated intracranial pressure.
• In January 2025, SeaStar Medical Holding Corporation announced that the FDA approved its investigational device exemption (IDE) application for the Selective Cytopheretic Device (SCD-ADULT). The device will be evaluated for its safety and efficacy in reducing inflammation in adult patients with acute heart failure and worsening renal function due to cardiorenal syndrome or severe right ventricular failure awaiting LVAD implantation.
• In December 2024, Field Medical announced that its FieldForce ablation system received FDA Breakthrough Device designation and was accepted into the Total Product Life Cycle Advisory Program (TAP) pilot for treating sustained monomorphic scar-related ventricular tachycardia (VT).

To read more about the latest highlights related to the ventricular assist devices market, get a snapshot of the key highlights entailed in the global ventricular assist devices market report here https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ventricular Assist Devices Overview
Ventricular Assist Devices (VADs) are mechanical pumps designed to support heart function and maintain blood flow in individuals with weakened or failing hearts. These devices are primarily used in patients with advanced heart failure, either as a bridge to heart transplantation, a destination therapy for those ineligible for transplant, or as temporary support during recovery from cardiac events. VADs can support the left ventricle (LVAD), right ventricle (RVAD), or both (BiVAD), depending on the severity and location of the heart failure.

The global demand for VADs is growing due to the increasing prevalence of heart failure, limited availability of donor hearts, and advancements in device technology that have improved patient outcomes and reduced complications. Modern VADs are smaller, more durable, and capable of providing long-term circulatory support, enhancing both survival and quality of life. As heart failure cases continue to rise globally, particularly among aging populations, VADs play an increasingly critical role in the management of end-stage heart disease.

Ventricular Assist Devices Market Insights
North America is expected to hold a significant share of the global ventricular assist devices (VADs) market, driven by the rising incidence of heart failure and cardiovascular diseases linked to lifestyle changes, high processed food consumption, obesity, and an aging population prone to chronic conditions like diabetes and hypertension. According to the CDC (2022), heart disease remains a leading cause of death in the U.S., with approximately 659,000 deaths annually, highlighting the urgent need for effective treatments such as VADs, which provide mechanical support to failing hearts either as a bridge to transplant or as destination therapy.

The increasing prevalence of diabetes, a major risk factor for cardiovascular disease, further fuels market growth; the International Diabetes Federation (2021) estimates millions living with diabetes in North America, with many undiagnosed cases contributing to higher cardiovascular risk. Unhealthy diets and lifestyle habits also exacerbate chronic disease rates, increasing demand for advanced cardiac support devices. Additionally, technological innovations-such as enhanced infection control features and the integration of artificial intelligence-are making VADs more effective and user-friendly, further boosting their adoption. Collectively, these factors are expected to drive substantial growth in the North American VAD market during the forecast period.

To know more about why North America is leading the market growth in the ventricular assist devices market, get a snapshot of the ventricular assist devices market outlook here https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Ventricular Assist Devices Market Dynamics
The ventricular assist devices (VAD) market is experiencing growth driven by the rising global prevalence of cardiovascular diseases (CVDs) such as heart failure and stroke, fueled by factors including genetics, aging populations, obesity, and unhealthy lifestyles. According to the WHO, CVDs were responsible for 17.9 million deaths in 2019, accounting for 32% of all global deaths, with the majority occurring in low- and middle-income countries. Heart failure, affecting over 64 million people worldwide, weakens cardiac muscles and often requires heart transplantation, but due to limited organ availability, VADs serve as critical support devices either as a bridge to transplant or as a long-term treatment. The increasing rates of obesity, projected to affect over a billion adults by 2025, further exacerbate cardiovascular risks by raising cholesterol, blood pressure, and diabetes rates.

Additionally, the growing geriatric population-expected to reach 1.4 billion by 2032 and 2.1 billion by 2050-also contributes to the increased burden of heart diseases. Government support and new product launches, such as Abbott's FDA Breakthrough Designation for its Fully Implantable Left Ventricular Assist System, are expected to boost market demand. However, high device costs and associated risks like bleeding and stroke may hinder growth. The COVID-19 pandemic temporarily disrupted elective surgeries and supply chains, limiting device availability, but with recovery and widespread vaccination, market momentum has resumed. Overall, these factors collectively are driving the expansion of the VAD market globally.

Get a sneak peek at the ventricular assist devices market dynamics @ https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coverage: Global
Study Period: 2022 to 2032
Ventricular Assist Devices Market CAGR: ~8.12%
Key Ventricular Assist Devices Companies: Abiomed, Inc., Asahi Kasei Corporation (Evaheart Medical U.S.A., Inc.), Abbott Laboratories (St. Jude Medical, Inc.), Berlin Heart GmbH, Jarvik Heart, Inc., Medtronic Plc., Terumo Corporation, Evaheart, Inc., Calon Cardio, SynCardia Systems LLC, Cardiobridge Gmbhand, LivaNova, Inc., Cirtec, CorWave SA, FineHeart, ReliantHeart Inc., and others.

Ventricular Assist Devices Market Segmentation
Market Segmentation By Product Type: Left Ventricular Assist Devices, Right Ventricular Assist Devices, and Biventricular Assist Devices.
Market Segmentation By Application: Bridge-To-Transplant [Btt], Destination Therapy, and others.
Market Segmentation By Design Type: Transcutaneous Ventricular Assist Devices and Implantable Ventricular Assist Devices.
Market Segmentation By Type of Flow: Pulsatile Flow and Continuous Flow.
Market Segmentation By End-User: Hospital And Clinics, Ambulatory Surgical Centers, and Others
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the ventricular assist devices market are set to emerge as the trendsetter, explore @ https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Ventricular Assist Devices Market Report Introduction
2. Ventricular Assist Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Ventricular Assist Devices Market Key Factors Analysis
6. Ventricular Assist Devices Market Porter's Five Forces Analysis
7. Ventricular Assist Devices Market Layout
8. Ventricular Assist Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Us
Jatin Vimal
jvimal@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.